WallStreetZenWallStreetZen

NASDAQ: KALV
Kalvista Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for KALV

Based on 5 analysts offering 12 month price targets for Kalvista Pharmaceuticals Inc

Min Forecast
$20.00+31.41%
Avg Forecast
$26.40+73.46%
Max Forecast
$30.00+97.11%

Should I buy or sell KALV stock?

Based on 5 analysts offering ratings for Kalvista Pharmaceuticals Inc.

Buy
Strong Buy
1 analysts 20%
Buy
4 analysts 80%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although KALV's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates KALV as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their KALV stock forecasts and price targets.

KALV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-07-11
lockedlocked$00.00+00.00%2025-07-08
lockedlocked$00.00+00.00%2025-07-07
lockedlocked$00.00+00.00%2025-04-08
lockedlocked$00.00+00.00%2025-03-26

1 of 1

Forecast return on equity

Is KALV forecast to generate an efficient return?

Company
47.13%
Industry
167.34%
Market
90.24%
KALV's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is KALV forecast to generate an efficient return on assets?

Company
17.93%
Industry
44.32%
KALV is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KALV earnings per share forecast

What is KALV's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$2.88
Avg 2 year Forecast
-$0.88
Avg 3 year Forecast
$0.90

KALV revenue forecast

What is KALV's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$47.9M
Avg 2 year Forecast
$151.0M
Avg 3 year Forecast
$276.7M

KALV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KALV$15.22$26.40+73.46%Buy
VIR$5.50$37.60+583.64%Strong Buy
CRMD$11.36$17.00+49.65%Buy
AMLX$8.41$12.17+44.67%Strong Buy
ORIC$10.85$17.75+63.59%Strong Buy
View Top Biotech Stocks

Kalvista Pharmaceuticals Stock Forecast FAQ

Is Kalvista Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: KALV) stock is to Buy KALV stock.

Out of 5 analysts, 1 (20%) are recommending KALV as a Strong Buy, 4 (80%) are recommending KALV as a Buy, 0 (0%) are recommending KALV as a Hold, 0 (0%) are recommending KALV as a Sell, and 0 (0%) are recommending KALV as a Strong Sell.

If you're new to stock investing, here's how to buy Kalvista Pharmaceuticals stock.

What is KALV's earnings growth forecast for 2026-2028?

(NASDAQ: KALV) Kalvista Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.7%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.83%.

Kalvista Pharmaceuticals's earnings in 2025 is -$183,444,000.On average, 7 Wall Street analysts forecast KALV's earnings for 2026 to be -$143,866,768, with the lowest KALV earnings forecast at -$187,326,521, and the highest KALV earnings forecast at -$85,420,894. On average, 3 Wall Street analysts forecast KALV's earnings for 2027 to be -$43,794,443, with the lowest KALV earnings forecast at -$65,439,398, and the highest KALV earnings forecast at -$7,493,061.

In 2028, KALV is forecast to generate $44,958,365 in earnings, with the lowest earnings forecast at $8,991,673 and the highest earnings forecast at $80,925,057.

What is KALV's revenue growth forecast for 2026-2028?

(NASDAQ: KALV) Kalvista Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.

Kalvista Pharmaceuticals's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast KALV's revenue for 2026 to be $2,393,633,312, with the lowest KALV revenue forecast at $787,270,927, and the highest KALV revenue forecast at $4,316,502,587. On average, 3 Wall Street analysts forecast KALV's revenue for 2027 to be $7,545,162,600, with the lowest KALV revenue forecast at $6,593,893,548, and the highest KALV revenue forecast at $9,079,591,601.

In 2028, KALV is forecast to generate $13,824,447,500 in revenue, with the lowest revenue forecast at $12,983,476,303 and the highest revenue forecast at $14,665,418,696.

What is KALV's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: KALV) forecast ROA is 17.93%, which is lower than the forecast US Biotechnology industry average of 44.32%.

What is KALV's Price Target?

According to 5 Wall Street analysts that have issued a 1 year KALV price target, the average KALV price target is $26.40, with the highest KALV stock price forecast at $30.00 and the lowest KALV stock price forecast at $20.00.

On average, Wall Street analysts predict that Kalvista Pharmaceuticals's share price could reach $26.40 by Jul 11, 2026. The average Kalvista Pharmaceuticals stock price prediction forecasts a potential upside of 73.46% from the current KALV share price of $15.22.

What is KALV's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: KALV) Kalvista Pharmaceuticals's current Earnings Per Share (EPS) is -$3.69. On average, analysts forecast that KALV's EPS will be -$2.88 for 2026, with the lowest EPS forecast at -$3.75, and the highest EPS forecast at -$1.71. On average, analysts forecast that KALV's EPS will be -$0.88 for 2027, with the lowest EPS forecast at -$1.31, and the highest EPS forecast at -$0.15. In 2028, KALV's EPS is forecast to hit $0.90 (min: $0.18, max: $1.62).

What is KALV's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: KALV) forecast ROE is 47.13%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.